HER2 gastric cancer: Unraveling resistance at single-cell resolution

HER2 gastric cancer: Unraveling resistance at single-cell resolution

HER2-positive gastric cancer accounts for a substantial proportion of advanced cases and has long been treated with HER2-targeted therapies.

From Early Escape to Immune Evasion: Mapping Drug Resistance in Advanced Gastric Cancer

A next-generation antibody–drug conjugate has transformed treatment for HER2-positive gastric cancer, yet many patients fail to benefit or relapse rapidly. Using single-cell analysis of patient tumor samples, researchers uncovered distinct mechanisms that drive both early and late resistance to trastuzumab deruxtecan. The study shows that tumors resistant from the outset are marked by a mucus-associated protein that limits drug binding, while can